Table of Contents
Chapter 1 Research Methodology
1.1 Market Segmentation & Scope
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 Objectives
1.11.1 Objective 1:
1.11.2 Objective 2:
1.12 List Of Abbreviations
Chapter 2 Market Definitions
Chapter 3 Executive Summary
3.1 Market Summary
Chapter 4 Global Hearing Loss Disease Treatment Market Variables, Trends, & Scope
4.1 Hearing Loss Disease Treatment Market Lineage Outlook
4.1.1 Parent Market Outlook
4.2 Penetration and Growth Prospect Mapping
4.3 Regulatory Framework
4.4 Market Driver Analysis
4.4.1 Rising Prevalence Of Hearing Loss
4.4.2 Strong R&D Pipeline
4.4.3 Rising Awarness Amoung People
4.5 Market Restraint Analysis
4.5.1 Poor Reimbursement Facilities In Low – And Middle-Income Countries
4.6 Porter’s Five Forces Analysis
4.7 Pipeline Analysis
Chapter 5 Hearing Loss Disease Treatment Market – Segment Analysis, By Product, 2018 – 2030 (USD Million)
5.1 Global Hearing Loss Disease Treatment Market: Product Movement Analysis
5.2. Devices
5.2.1. Devices Market Estimates And Forecasts, 2018 – 2030 (USD Million)
5.3. Drugs
5.3.1. Drugs Market Estimates And Forecasts, 2018 – 2030 (USD Million)
5.3.2 Systemic Steroids
5.3.2.1 Systemic Steroids Market Estimates And Forecasts, 2018 – 2030 (USD Million)
5.3.3 Antiviral Medication
5.3.3.1 Antiviral Medication Market Estimates And Forecasts, 2018 – 2030 (USD Million)
5.3.4 Vasodilators
5.3.4.1 Vasodilators Market Estimates And Forecasts, 2018 – 2030 (USD Million)
5.3.5 Others
5.3.5.1 Others Market Estimates And Forecasts, 2018 – 2030 (USD Million)
Chapter 6 Hearing Loss Disease Treatment – Segment Analysis, By Disease Type, 2018 – 2030 (USD Million)
6.1. Hearing Loss Disease Treatment Market Share, By Disease Type, 2018 & 2030
6.2. Conductive Hearing Loss
6.2.1. Conductive Hearing Loss Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.3. Sensorineural Hearing Loss Mixed
6.3.1. Sensorineural Hearing Loss Mixed Market Estimates And Forecasts, 2018 – 2030 (USD Million)
6.3. Mixed (Conductive And Sensorineural)
6.3.1. Mixed (Conductive And Sensorineural) Market Estimates And Forecasts, 2018 – 2030 (USD Million)
Chapter 7 Hearing Loss Disease Treatment Market- Segment Analysis, By End-User, 2018 – 2030 (USD Million)
7.1. Hospitals
7.1.1 Hospitals Market Estimates And Forecasts, 2018 – 2030 (USD Million)
7.2. Otology Clinics, 2018 – 2030
7.2.1 Otology Clinics Market Estimates And Forecasts, 2018 – 2030 (USD Million)
7.3. Ambulatory Clinics, 2018 – 2030
7.3.1 Ambulatory Clinics Market Estimates And Forecasts, 2018 – 2030 (USD Million)
Chapter 8 Hearing Loss Disease Treatment Market: – Segment Analysis, by Region, 2018 – 2030 (USD Million)
8.1 Definition & Scope
8.2 North America
8.2.1 North America, SWOT Analysis
8.2.2 U.S.
8.2.2.1 U.S. market estimates and forecast, 2018 – 2030 (USD Million)
8.2.2.2 Key Country Dynamics
8.2.2.3 Target Disease Prevalence
8.2.2.4 Competitive Scenario
8.2.2.5 Regulatory Framework
8.2.2.6 Reimbursment Scenario
8.2.3 Canada
8.2.3.1 Canada market estimates and forecast, 2018 – 2030 (USD Million)
8.2.3.2 Key Country Dynamics
8.2.3.3 Target Disease Prevalence
8.2.3.4 Competitive Scenario
8.2.3.5 Regulatory Framework
8.2.3.6 Reimbursment Scenario
8.3 Europe
8.3.1 Europe, SWOT Analysis
8.3.2 U.K.
8.3.2.1 U.K. market estimates and forecast, 2018 – 2030 (USD Million)
8.3.2.2 Key Country Dynamics
8.3.2.3 Target Disease Prevalence
8.3.2.4 Competitive Scenario
8.3.2.5 Regulatory Framework
8.3.2.6 Reimbursment Scenario
8.3.3 Germany
8.3.3.1 Germany market estimates and forecast, 2018 – 2030 (USD Million)
8.3.3.2 Key Country Dynamics
8.3.3.3 Target Disease Prevalence
8.3.3.4 Competitive Scenario
8.3.3.5 Regulatory Framework
8.3.3.6 Reimbursment Scenario
8.3.4 France
8.3.4.1 France market estimates and forecast, 2018 – 2030 (USD Million)
8.3.4.2 Key Country Dynamics
8.3.4.3 Target Disease Prevalence
8.3.4.4 Competitive Scenario
8.3.4.5 Regulatory Framework
8.3.4.6 Reimbursment Scenario
8.3.5 Italy
8.3.5.1 Italy market estimates and forecast, 2018 – 2030 (USD Million)
8.3.5.2 Key Country Dynamics
8.3.5.3 Target Disease Prevalence
8.3.5.4 Competitive Scenario
8.3.5.5 Regulatory Framework
8.3.5.6 Reimbursment Scenario
8.3.6 Spain
8.3.6.1 Spain market estimates and forecast, 2018 – 2030 (USD Million)
8.3.6.2 Key Country Dynamics
8.3.6.3 Target Disease Prevalence
8.3.6.4 Competitive Scenario
8.3.6.5 Regulatory Framework
8.3.6.6 Reimbursment Scenario
8.3.7 Sweden
8.3.7.1 Sweden market estimates and forecast, 2018 – 2030 (USD Million)
8.3.7.2 Key Country Dynamics
8.3.7.3 Target Disease Prevalence
8.3.7.4 Competitive Scenario
8.3.7.5 Regulatory Framework
8.3.7.6 Reimbursment Scenario
8.3.8 Denmark
8.3.8.1 Denmark market estimates and forecast, 2018 – 2030 (USD Million)
8.3.8.2 Key Country Dynamics
8.3.8.3 Target Disease Prevalence
8.3.8.4 Competitive Scenario
8.3.8.5 Regulatory Framework
8.3.8.6 Reimbursment Scenario
8.3.9 Norway
8.3.9.1 Norway market estimates and forecast, 2018 – 2030 (USD Million)
8.3.9.2 Key Country Dynamics
8.3.9.3 Target Disease Prevalence
8.3.9.4 Competitive Scenario
8.3.9.5 Regulatory Framework
8.3.9.6 Reimbursment Scenario
8.3.10 Rest of Europe
8.4 Asia Pacific
8.4.1 Asia Pacific, SWOT Analysis
8.4.2 India
8.4.2.1 India market estimates and forecast, 2018 – 2030 (USD Million)
8.4.2.2 Key Country Dynamics
8.4.2.3 Target Disease Prevalence
8.4.2.4 Competitive Scenario
8.4.2.5 Regulatory Framework
8.4.2.6 Reimbursment Scenario
8.4.3 China
8.4.3.1 China market estimates and forecast, 2018 – 2030 (USD Million)
8.4.3.2 Key Country Dynamics
8.4.3.3 Target Disease Prevalence
8.4.3.4 Competitive Scenario
8.4.3.5 Regulatory Framework
8.4.3.6 Reimbursment Scenario
8.4.4 Japan
8.4.4.1 Japan market estimates and forecast, 2018 – 2030 (USD Million)
8.4.4.2 Key Country Dynamics
8.4.4.3 Target Disease Prevalence
8.4.4.4 Competitive Scenario
8.4.4.5 Regulatory Framework
8.4.4.6 Reimbursment Scenario
8.4.5 Australia
8.4.5.1 Australia market estimates and forecast, 2018 – 2030 (USD Million)
8.4.5.2 Key Country Dynamics
8.4.5.3 Target Disease Prevalence
8.4.5.4 Competitive Scenario
8.4.5.5 Regulatory Framework
8.4.5.6 Reimbursment Scenario
8.4.6 South Korea
8.4.6.1 South Korea market estimates and forecast, 2018 – 2030 (USD Million)
8.4.6.2 Key Country Dynamics
8.4.6.3 Target Disease Prevalence
8.4.6.4 Competitive Scenario
8.4.6.5 Regulatory Framework
8.4.6.6 Reimbursment Scenario
8.4.7 Thailand
8.4.7.1 Thailand market estimates and forecast, 2018 – 2030 (USD Million)
8.4.7.2 Key Country Dynamics
8.4.7.3 Target Disease Prevalence
8.4.7.4 Competitive Scenario
8.4.7.5 Regulatory Framework
8.4.7.6 Reimbursment Scenario
8.5 Latin America
8.5.1 Latin America, SWOT Analysis
8.5.2 Mexico
8.5.2.1 Mexico market estimates and forecast, 2018 – 2030 (USD Million)
8.5.2.2 Key Country Dynamics
8.5.2.3 Target Disease Prevalence
8.5.2.4 Competitive Scenario
8.5.2.5 Regulatory Framework
8.5.2.6 Reimbursment Scenario
8.5.3 Brazil
8.5.3.1 Brazil market estimates and forecast, 2018 – 2030 (USD Million)
8.5.3.2 Key Country Dynamics
8.5.3.3 Target Disease Prevalence
8.5.3.4 Competitive Scenario
8.5.3.5 Regulatory Framework
8.5.3.6 Reimbursment Scenario
8.5.4 Argentina
8.5.4.1 Argentina market estimates and forecast, 2018 – 2030 (USD Million)
8.5.4.2 Key Country Dynamics
8.5.4.3 Target Disease Prevalence
8.5.4.4 Competitive Scenario
8.5.4.5 Regulatory Framework
8.5.4.6 Reimbursment Scenario
8.6 MEA
8.6.1 Middle East & Africa, SWOT Analysis
8.6.2 South Africa
8.6.2.1 South Africa market estimates and forecast, 2018 – 2030 (USD Million)
8.6.2.2 Key Country Dynamics
8.6.2.3 Target Disease Prevalence
8.6.2.4 Competitive Scenario
8.6.2.5 Regulatory Framework
8.6.2.6 Reimbursment Scenario
8.6.3 Saudi Arabia
8.6.3.1 Saudi Arabia market estimates and forecast, 2018 – 2030 (USD Million)
8.6.3.2 Key Country Dynamics
8.6.3.3 Target Disease Prevalence
8.6.3.4 Competitive Scenario
8.6.3.5 Regulatory Framework
8.6.3.6 Reimbursment Scenario
8.6.4 UAE
8.6.4.1 UAE market estimates and forecast, 2018 – 2030 (USD Million)
8.6.4.2 Key Country Dynamics
8.6.4.3 Target Disease Prevalence
8.6.4.4 Competitive Scenario
8.6.4.5 Regulatory Framework
8.6.4.6 Reimbursment Scenario
8.6.5 Kuwait
8.6.5.1 Kuwait market estimates and forecast, 2018 – 2030 (USD Million)
8.6.5.2 Key Country Dynamics
8.6.5.3 Target Disease Prevalence
8.6.5.4 Competitive Scenario
8.6.5.5 Regulatory Framework
8.6.5.6 Reimbursment Scenario
Chapter 9 Competitive Landscape
9.1 Public Companies
9.1.1 Company Market Position Analysis
9.1.2 Competitive Dashboard Analysis
9.1.3 Strategic Framework
9.2 Private Companies
9.2.1 List Of Key Emerging Companies/Technology Disruptors/Innovators
9.2.2 Regional Network Map
9.3 Company Profiles
9.3.1 Novartis Ag
9.3.1.1 Company Overview
9.3.1.2 Financial Performance
9.3.1.3 Product Benchmarking
9.3.1.4 Strategic Initiatives
9.3.2 Otonomy, Inc
9.3.2.1 Company Overview
9.3.2.2 Financial Performance
9.3.2.3 Product Benchmarking
9.3.2.4 Strategic Initiatives
9.3.3 Acousia Therapeutics Gmbh
9.3.3.1 Company Overview
9.3.3.2 Financial Performance
9.3.3.3 Product Benchmarking
9.3.3.4 Strategic Initiatives
9.3.4 Sensorion
9.3.4.1 Company Overview
9.3.4.2 Financial Performance
9.3.4.3 Product Benchmarking
9.3.4.4 Strategic Initiatives
9.3.5 Pipeline Therapeutics
9.3.5.1 Company Overview
9.3.5.2 Financial Performance
9.3.5.3 Product Benchmarking
9.3.5.4 Strategic Initiatives
9.3.6 Frequency Therapeutics
9.3.6.1 Company Overview
9.3.6.2 Financial Performance
9.3.6.3 Product Benchmarking
9.3.6.4 Strategic Initiatives
9.3.7 Astellas Pharma Inc
9.3.7.1 Company Overview
9.3.7.2 Financial Performance
9.3.7.3 Product Benchmarking
9.3.7.4 Strategic Initiatives
9.3.8 Audina Hearing Instruments, Inc.
9.3.8.1 Company Overview
9.3.8.2 Financial Performance
9.3.8.3 Product Benchmarking
9.3.8.4 Strategic Initiatives
9.3.9 Ws Audiology A/S
9.3.9.1 Company Overview
9.3.9.2 Financial Performance
9.3.9.3 Product Benchmarking
9.3.9.4 Strategic Initiatives
9.3.10 Audifon Gmbh & Co. Kg
9.3.10.1 Company Overview
9.3.10.2 Financial Performance
9.3.10.3 Product Benchmarking
9.3.10.4 Strategic Initiatives
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer